PHARMA COMPANIES TO DEVELOP FLU VACCINES WITH ADJUVANT

FEBRUARY 01, 2007

The US Department of Health and Human Services has awarded $132.5 million to 3 pharmaceutical companies for the advanced development of H5N1 influenza vaccines using an adjuvant—an immune system booster. The government has given the companies the task of developing bird-flu vaccines using adjuvants, which increase the body's immune response. Less of this type of vaccine should be required for protection.

The agency awarded $54.8 million to Novartis, $63.3 million to GlaxoSmith- Kline, and $14.4 million to Iomai of Maryland. Under the contracts, each company will increase its capacity to produce—within 6 months after the start of an influenza pandemic—either 150 million doses of an adjuvant-based pandemic influenza vaccine or sufficient adjuvant for 150 million doses of a pandemic influenza vaccine.




SHARE THIS SHARE THIS
0
 

AF Risk Increases with More Pregnancies

One study linked multiple pregnancies to an increased risk of developing atrial fibrillation later in life, and another investigated the association between premature delivery and cardiovascular disease.


 

Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


 

SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.